The biological variation of insulin resistance markers: data from the European Biological Variation Study (EuBIVAS).

IF 3.8 2区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Clinical chemistry and laboratory medicine Pub Date : 2024-07-12 DOI:10.1515/cclm-2024-0672

Anna Carobene, Eric Kilpatrick, William A Bartlett, Pilar Fernández Calle, Abdurrahman Coşkun, Jorge Díaz-Garzón, Niels Jonker, Massimo Locatelli, Sverre Sandberg, Aasne K Aarsand

{"title":"The biological variation of insulin resistance markers: data from the European Biological Variation Study (EuBIVAS).","authors":"Anna Carobene, Eric Kilpatrick, William A Bartlett, Pilar Fernández Calle, Abdurrahman Coşkun, Jorge Díaz-Garzón, Niels Jonker, Massimo Locatelli, Sverre Sandberg, Aasne K Aarsand","doi":"10.1515/cclm-2024-0672","DOIUrl":null,"url":null,"abstract":"Objectives: An insulin resistant state is characteristic of patients with type 2 diabetes, polycystic ovary syndrome, and metabolic syndrome. Identification of insulin resistance (IR) is most readily achievable using formulae combining plasma insulin and glucose results. In this study, we have used data from the European Biological Variation Study (EuBIVAS) to examine the biological variability (BV) of IR using the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) and the Quantitative Insulin sensitivity Check Index (QUICKI).Methods: Ninety EuBIVAS non-diabetic subjects (52F, 38M) from five countries had fasting HOMA-IR and QUICKI calculated from plasma glucose and insulin samples collected concurrently on 10 weekly occasions. The within-subject (CVI) and between-subject (CVG) BV estimates with 95 % CIs were obtained by CV-ANOVA after analysis of trends, variance homogeneity and outlier removal.Results: The CVI of HOMA-IR was 26.7 % (95 % CI 25.5-28.3), driven largely by variability in plasma insulin and the CVI for QUICKI was 4.1 % (95 % CI 3.9-4.3), reflecting this formula's logarithmic transformation of glucose and insulin values. No differences in values or BV components were observed between subgroups of men or women below and above 50 years.Conclusions: The EuBIVAS, by utilising a rigorous experimental protocol, has produced robust BV estimates for two of the most commonly used markers of insulin resistance in non-diabetic subjects. This has shown that HOMA-IR, in particular, is highly variable in the same individual which limits the value of single measurements.","PeriodicalId":10390,"journal":{"name":"Clinical chemistry and laboratory medicine","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry and laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/cclm-2024-0672","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: An insulin resistant state is characteristic of patients with type 2 diabetes, polycystic ovary syndrome, and metabolic syndrome. Identification of insulin resistance (IR) is most readily achievable using formulae combining plasma insulin and glucose results. In this study, we have used data from the European Biological Variation Study (EuBIVAS) to examine the biological variability (BV) of IR using the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) and the Quantitative Insulin sensitivity Check Index (QUICKI).

Methods: Ninety EuBIVAS non-diabetic subjects (52F, 38M) from five countries had fasting HOMA-IR and QUICKI calculated from plasma glucose and insulin samples collected concurrently on 10 weekly occasions. The within-subject (CV_I) and between-subject (CV_G) BV estimates with 95 % CIs were obtained by CV-ANOVA after analysis of trends, variance homogeneity and outlier removal.

Results: The CV_I of HOMA-IR was 26.7 % (95 % CI 25.5-28.3), driven largely by variability in plasma insulin and the CV_I for QUICKI was 4.1 % (95 % CI 3.9-4.3), reflecting this formula's logarithmic transformation of glucose and insulin values. No differences in values or BV components were observed between subgroups of men or women below and above 50 years.

Conclusions: The EuBIVAS, by utilising a rigorous experimental protocol, has produced robust BV estimates for two of the most commonly used markers of insulin resistance in non-diabetic subjects. This has shown that HOMA-IR, in particular, is highly variable in the same individual which limits the value of single measurements.

查看原文本刊更多论文

胰岛素抵抗标志物的生物变异：欧洲生物变异研究（EuBIVAS）的数据。

目的：胰岛素抵抗状态是 2 型糖尿病、多囊卵巢综合征和代谢综合征患者的特征。使用结合血浆胰岛素和血糖结果的公式最容易确定胰岛素抵抗（IR）。在这项研究中，我们利用欧洲生物变异研究（EuBIVAS）的数据，采用胰岛素抵抗的稳态模型评估（HOMA-IR）和胰岛素敏感性定量检查指数（QUICKI），研究了IR的生物变异性（BV）：来自 5 个国家的 90 名 EuBIVAS 非糖尿病受试者（52 名女性，38 名男性）通过每周 10 次同时采集的血浆葡萄糖和胰岛素样本计算空腹 HOMA-IR 和 QUICKI。在对趋势、方差均一性和异常值进行分析后，通过 CV-ANOVA 得出了受试者内（CVI）和受试者间（CVG）BV 估计值及 95 % CI：HOMA-IR 的 CVI 为 26.7 %（95 % CI 25.5-28.3），主要受血浆胰岛素变异的影响；QUICKI 的 CVI 为 4.1 %（95 % CI 3.9-4.3），反映了该公式对葡萄糖和胰岛素值的对数转换。在 50 岁以下和 50 岁以上的男性或女性亚组之间，没有观察到数值或 BV 成分的差异：EuBIVAS 采用严格的实验方案，对非糖尿病受试者胰岛素抵抗最常用的两个指标进行了可靠的 BV 估算。这表明，HOMA-IR 在同一个人身上的变化尤其大，这限制了单次测量的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical chemistry and laboratory medicine 医学-医学实验技术

CiteScore

11.30

自引率

16.20%

发文量

306

审稿时长

3 months

期刊介绍： Clinical Chemistry and Laboratory Medicine (CCLM) publishes articles on novel teaching and training methods applicable to laboratory medicine. CCLM welcomes contributions on the progress in fundamental and applied research and cutting-edge clinical laboratory medicine. It is one of the leading journals in the field, with an impact factor over 3. CCLM is issued monthly, and it is published in print and electronically. CCLM is the official journal of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and publishes regularly EFLM recommendations and news. CCLM is the official journal of the National Societies from Austria (ÖGLMKC); Belgium (RBSLM); Germany (DGKL); Hungary (MLDT); Ireland (ACBI); Italy (SIBioC); Portugal (SPML); and Slovenia (SZKK); and it is affiliated to AACB (Australia) and SFBC (France). Topics: - clinical biochemistry - clinical genomics and molecular biology - clinical haematology and coagulation - clinical immunology and autoimmunity - clinical microbiology - drug monitoring and analysis - evaluation of diagnostic biomarkers - disease-oriented topics (cardiovascular disease, cancer diagnostics, diabetes) - new reagents, instrumentation and technologies - new methodologies - reference materials and methods - reference values and decision limits - quality and safety in laboratory medicine - translational laboratory medicine - clinical metrology Follow @cclm_degruyter on Twitter!